Ubidecarenone - Berg Pharma

Drug Profile

Ubidecarenone - Berg Pharma

Alternative Names: API-31510; BP 31510; BPM 31510-IV; BPM-31510; C-31510; c31510; Coenzyme Q10 - Cytotech; Coenzyme Q10 injectable nanosuspension; Compound 31510; CoQ10 - Cytotech; Ubiquinone injectable nanosuspension

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytotech Labs
  • Developer Berg Pharma; National Cancer Institute (USA); Stanford University; University of Miami
  • Class Antihyperlipidaemics; Antineoplastics; Benzoquinones; Cardiotonics; Cardiovascular therapies; Coenzymes; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Electron transport chain complex protein modulators; Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Glioblastoma; Glioma
  • Phase I Epidermolysis bullosa; Solid tumours
  • No development reported Basal cell cancer; Lung cancer; Squamous cell cancer; Wounds
  • Discontinued Leukaemia

Most Recent Events

  • 01 Jun 2018 Efficacy, adverse events and pharmacokinetics data from a phase I trial in a Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 23 May 2018 Ubidecarenone - Berg Pharma receives Orphan Drug status for Epidermolysis bullosa in USA
  • 21 Apr 2018 Adverse events and pharmacokinetics data from a preclinical trial in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top